LFG
CTXR icon

Larson Financial Group’s Citius Pharmaceuticals CTXR Stock Holding History

Larson Financial Group’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45
Closed -$72 – 3494
2025
Q2 		$72 Buy
+45
New +$41 ﹤0.01% 3199

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Larson Financial Group's CTXR Position: Q3 2025 in Review

Larson Financial Group sold out of Citius Pharmaceuticals (CTXR) in Q3 2025, closing a stake of 45 shares — an estimated $72 sold.

Larson Financial Group first reported a position in CTXR in Q2 2025 and held it in 1 quarter. The position peaked at $72 in Q2 2025. 34 funds tracked by Wall St. Rank hold CTXR as of Q3 2025.

  • Larson Financial Group reported no remaining Citius Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Larson Financial Group sold 45 Citius Pharmaceuticals shares in Q3 2025, an estimated $72.
  • Larson Financial Group first reported a position in Citius Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Larson Financial Group's Citius Pharmaceuticals position peaked at $72 in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2025.

Based on Larson Financial Group's 13F filing for Q3 2025, filed 14 Nov 2025.